SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jay silberman who wrote (1288)10/1/1997 6:51:00 PM
From: Brad C. Dunlap   of 1762
 
HI Jay, the following are a few events to look forward to by year end.
1] FDA approval of Rituxin. All manufacturing info should be
completed by the end of october and submitted to FDA
2] rituxin/chop updated info from previous reported phase II
study on low grade nhl.
3] rituxin/yb28 results on low grade nhl. Abstracts submitted
to american society of hematology conference in december.
4] results of a small study of patients retreated with rituxin. This imo
will be huge for the stock if positive.
5] rituxin/chop on intermediate grade nhl patients.
6] IND on gp-39. Unknown undication.

Good times should continue.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News